Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 125

Sort by

Sort Order Select

Journal Articles

Chronic Myeloid Leukemia Diagnosed during Pregnancy: How to Manage? Description of 86 Cases from ELN International Registry

Blood (2022) 140 (Supplement 1): 1498–1500.

https://doi.org/10.1182/blood-2022-159993

Published: 2022

Journal Articles

Dynamics of Response and Response Factors in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase 3 Ascembl Study

Timothy Hughes, Delphine Rea, Carla Boquimpani, Yosuke Minami, Michael Mauro, Jorge E. Cortes, Jane F. Apperley, Valentín García Gutiérrez, Shruti Kapoor, Alex Allepuz, Sarah Quenet, Yifan Zhang, Andreas Hochhaus

Blood (2022) 140 (Supplement 1): 6757–6759.

https://doi.org/10.1182/blood-2022-169110

Published: 2022

Journal Articles

A Risk Model for CML Patients with COVID-19: Importance of Molecular Response in the Context of Age, Comorbidities and Country Income

Jerald P. Radich, Chung Hoow Kok, Ekaterina Yu. Chelysheva, Jorge E. Cortes, Qian Jiang, Michael Mauro, Dragana Milojkovic, Beatriz Moiraghi, Franck E. Nicolini, Matilda Ongondi, Katia B Pagnano, Daniela Žácková, Delphine Rea, Nicola Evans, Timothy Hughes

Blood (2022) 140 (Supplement 1): 9617–9619.

https://doi.org/10.1182/blood-2022-165855

Published: 2022

Journal Articles

Impact of NFE2 mutations on AML transformation and overall survival in patients with myeloproliferative neoplasms

Blood (2021) 138 (21): 2142–2148.

https://doi.org/10.1182/blood.2020010402

Published: 2021

Includes: Supplemental data

Journal Articles

A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs

Blood (2021) 138 (21): 2031–2041.

https://doi.org/10.1182/blood.2020009984

Published: 2021

Includes: Supplemental data

Journal Articles

Treatment Free Survival (TFS) in Patients (pts) with Chronic Myeloid Leukemia (CML) Carrying Atypical BCR-ABL1 Fusion Transcripts: The French CML Group (Fi-LMC) Experience

Hyacinthe Johnson-Ansah, Aude Charbonnier, Delphine Rea, Gabriel Etienne, Lydia Roy, Laurence Legros, Agnes Guerci Bresler, Anne Bouvier, Emilie Cayssials, Valerie Coiteux, Philippe Rousselot, Stephanie Dulucq, Sandrine Hayette, Francois-Xavier Mahon, Franck E. Nicolini

Blood (2021) 138 (Supplement 1): 3604.

https://doi.org/10.1182/blood-2021-147537

Published: 2021

Journal Articles

Treatment-Free Remission (TFR) after Two Different Durations of Nilotinib Consolidation in Patients with Chronic Myeloid Leukemia (CML) Previously Treated with Imatinib: Enestpath Study Results

Delphine Rea, Slawomira Kyrcz-Krzemien, Paolo Sportoletti, Jiří Mayer, Arpad Illes, Anna Angona, Alexander Kiani, Aude Charbonnier, Theodoros Marinakis, Leif Stenke, Ansgar Weltermann, Seema Shah, Sharon Supekar, Luigi Di Caprio, Michele Baccarani

Blood (2021) 138 (Supplement 1): 635.

https://doi.org/10.1182/blood-2021-145611

Published: 2021

Journal Articles

COVID-19 in Patients with Chronic Myeloid Leukemia: Poor Outcomes for Patients with Comorbidities, Older Age, Advanced Phase Disease, and Those from Low-Income Countries: An Update of the Candid Study

Katia B Pagnano, Chung Hoow Kok, Michael J. Mauro, Jorge E. Cortes, Nicola Evans, Qian Jiang, Dragana Milojkovic, Beatriz Moiraghi, Franck E. Nicolini, Matilda Ongondi, Daniela Zackova, Delphine Rea, Timothy P. Hughes

Blood (2021) 138 (Supplement 1): 634.

https://doi.org/10.1182/blood-2021-150026

Published: 2021

Journal Articles

Onset of Blast Crises in CML Patients in Treatment-Free Remission: Descriptive Analysis of 4 Cases

Stephanie Dulucq, Frédéric Bauduer, Jean-Michel Cayuela, Patrice Chevallier, Pascale Cony-Makhoul, Yannick Le Bris, Laurence Legros, Herve Maisonneuve, Lydia Roy, Francois-Xavier Mahon, Sandrine Hayette, Delphine Rea, Franck E. Nicolini

Blood (2021) 138 (Supplement 1): 2556.

https://doi.org/10.1182/blood-2021-149986

Published: 2021

Journal Articles

The Outcome of Treatment-Free Remission after First-Line Nilotinib or Dasatinib in Chronic Phase Chronic Myeloid Leukemia Patients Is Different

Franck E. Nicolini, Vincent Alcazer, Stephanie Dulucq, Sandrine Hayette, Jean-Michel Cayuela, Stephane Morisset, Christophe Bouvier, Francois-Xavier Mahon, Gabriel Etienne, Delphine Rea

Blood (2021) 138 (Supplement 1): 2552.

https://doi.org/10.1182/blood-2021-146722

Published: 2021

Journal Articles

Dose Modification Dynamics of Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) from the PACE and Optic Trials

Blood (2021) 138 (Supplement 1): 2550.

https://doi.org/10.1182/blood-2021-146175

Published: 2021

Journal Articles

Treatment-Free Remissions in Newly Diagnosed CP CML Patients Treated with the Combination of Nilotinib + Pegylated Interferon Alpha 2a Versus Nilotinib Alone in the National Phase III Petals Trial

Blood (2021) 138 (Supplement 1): 2553.

https://doi.org/10.1182/blood-2021-146412

Published: 2021

Journal Articles

Patient and Physician Perspectives of Unmet Needs in CML - Designing the CML SUN Survey

Zack Pemberton-Whiteley, Jorge E. Cortes, Joannie Clements, Cristina Ruiz, Delphine Rea, Lisa Machado, Fabian Lang, Naoto Takahashi, Nigel Deekes, Sung-Ho Moon, Andrew Grigg, Merula Steagall, Cornelia Borowczak, Virginia Pilipovic, Pauline Frank, Cristina Constantinescu, Carla Boquimpani

Blood (2021) 138 (Supplement 1): 4986.

https://doi.org/10.1182/blood-2021-147739

Published: 2021

Journal Articles

Efficacy and Safety Results from Ascembl, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, Vs Bosutinib in Patients with Chronic Myeloid Leukemia in Chronic Phase after ≥2 Prior Tyrosine Kinase Inhibitors: Update after 48 Weeks

Blood (2021) 138 (Supplement 1): 310.

https://doi.org/10.1182/blood-2021-152561

Published: 2021

Journal Articles

ETNK1 Mutations in Atypical Chronic Myeloid Leukemia Induce a Mutator Phenotype That Can be Reverted with Phosphoethanolamine

Blood (2020) 136 (Supplement_2): LBA-5.

https://doi.org/10.1182/blood-2020-143852

Published: 2020

Journal Articles

Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs

Blood (2020) 136 (Supplement_2): LBA-4.

https://doi.org/10.1182/blood-2020-143816

Published: 2020

Journal Articles

SF3B1 mutations in the Driver Clone Increase the Risk of Evolution to Myelofibrosis in Patients with Myeloproliferative Neoplasms (MPN)

Lin-Pierre Zhao, MD, Rafael Daltro De Oliveira, MD, Clemence Marcault, MD, Juliette Soret, MD, Nicolas Gauthier, MD, Emmanuelle Verger, PhD, Nabih Maslah, PharmD, Blandine Roux, MSc, Nathalie Parquet, MD, Christine Dosquet, MD, Delphine Rea, MDPhD, Jean-Marc Zini, MD, William Vainchenker, Emmanuel Raffoux, MD, Stephane Giraudier, MD PhD, Bruno Cassinat, PharmD, PhD, Jean-Jacques Kiladjian, MD PhD, Lina Benajiba, MD PhD

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-141296

Published: 2020

Journal Articles

NFE2 Mutations Impact AML Transformation and Overall Survival in Patients with Myeloproliferative Neoplasms (MPN)

Clemence Marcault, MD, Lin-Pierre Zhao, MD, Rafael Daltro De Oliveira, MD, Juliette Soret, MD, Nicolas Gauthier, MD, Emmanuelle Verger, PhD, Nabih Maslah, PharmD, Blandine Roux, MSc, Nathalie Parquet, MD, Christine Dosquet, MD, Delphine Rea, MDPhD, Jean-Marc Zini, William Vainchenker, Emmanuel Raffoux, MD, Stephane Giraudier, MD PhD, Bruno Cassinat, PharmD, PhD, Jean-Jacques Kiladjian, Lina Benajiba, MD PhD

Blood (2020) 136 (Supplement 1): 36.

https://doi.org/10.1182/blood-2020-136177

Published: 2020

Journal Articles

Efficacy and Safety of Ponatinib (PON) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Who Failed One or More Second-Generation (2G) Tyrosine Kinase Inhibitors (TKIs): Analyses Based on PACE and Optic

Blood (2020) 136 (Supplement 1): 43–44.

https://doi.org/10.1182/blood-2020-133922

Published: 2020

Journal Articles

COVID-19 in Patients (pts) with Chronic Myeloid Leukemia (CML): Results from the International CML Foundation (iCMLf) CML and COVID-19 (CANDID) Study

Delphine Rea, MDPhD, Michael J. Mauro, MD, Jorge E. Cortes, MD, Qian Jiang, MD, Katia B Pagnano, MDPhD, Matilda Ongondi, MD, Chung Hoow Kok, BSc, PhD, Nicola Evans, Timothy P. Hughes, MDMBBS,FRACP,FRCPA, International CML Foundation

Blood (2020) 136 (Supplement 1): 46–47.

https://doi.org/10.1182/blood-2020-140161

Published: 2020

NARROW

Chronic Myeloid Leukemia Diagnosed during Pregnancy: How to Manage? Description of 86 Cases from ELN International Registry

Dynamics of Response and Response Factors in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase 3 Ascembl Study

A Risk Model for CML Patients with COVID-19: Importance of Molecular Response in the Context of Age, Comorbidities and Country Income

Impact of NFE2 mutations on AML transformation and overall survival in patients with myeloproliferative neoplasms

A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs

Treatment Free Survival (TFS) in Patients (pts) with Chronic Myeloid Leukemia (CML) Carrying Atypical BCR-ABL1 Fusion Transcripts: The French CML Group (Fi-LMC) Experience

Treatment-Free Remission (TFR) after Two Different Durations of Nilotinib Consolidation in Patients with Chronic Myeloid Leukemia (CML) Previously Treated with Imatinib: Enestpath Study Results

COVID-19 in Patients with Chronic Myeloid Leukemia: Poor Outcomes for Patients with Comorbidities, Older Age, Advanced Phase Disease, and Those from Low-Income Countries: An Update of the Candid Study

Onset of Blast Crises in CML Patients in Treatment-Free Remission: Descriptive Analysis of 4 Cases

The Outcome of Treatment-Free Remission after First-Line Nilotinib or Dasatinib in Chronic Phase Chronic Myeloid Leukemia Patients Is Different

Dose Modification Dynamics of Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) from the PACE and Optic Trials

Treatment-Free Remissions in Newly Diagnosed CP CML Patients Treated with the Combination of Nilotinib + Pegylated Interferon Alpha 2a Versus Nilotinib Alone in the National Phase III Petals Trial

Patient and Physician Perspectives of Unmet Needs in CML - Designing the CML SUN Survey

Efficacy and Safety Results from Ascembl, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, Vs Bosutinib in Patients with Chronic Myeloid Leukemia in Chronic Phase after ≥2 Prior Tyrosine Kinase Inhibitors: Update after 48 Weeks

ETNK1 Mutations in Atypical Chronic Myeloid Leukemia Induce a Mutator Phenotype That Can be Reverted with Phosphoethanolamine

Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs

SF3B1 mutations in the Driver Clone Increase the Risk of Evolution to Myelofibrosis in Patients with Myeloproliferative Neoplasms (MPN)

NFE2 Mutations Impact AML Transformation and Overall Survival in Patients with Myeloproliferative Neoplasms (MPN)

Efficacy and Safety of Ponatinib (PON) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Who Failed One or More Second-Generation (2G) Tyrosine Kinase Inhibitors (TKIs): Analyses Based on PACE and Optic

COVID-19 in Patients (pts) with Chronic Myeloid Leukemia (CML): Results from the International CML Foundation (iCMLf) CML and COVID-19 (CANDID) Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only